Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units


Autoria(s): OLIVEIRA, João F. P.; SILVA, Carolina A; BARBIERI, Camila D; OLIVEIRA, Giselle M; ZANETTA, Dirce Maria Trevisan; BURDMANN, Emmanuel A.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

15/04/2012

15/04/2012

2009

Resumo

In order to assess the prevalence of and risk factors for aminoglycoside-associated nephrotoxicity in intensive care units (ICUs), we evaluated 360 consecutive patients starting aminoglycoside therapy in an ICU. The patients had a baseline calculated glomerular filtration rate (cGFR) of ?30 ml/min/1.73 m2. Among these patients, 209 (58 per cent) developed aminoglycoside-associated nephrotoxicity (the acute kidney injury [AKI] group, which consisted of individuals with a decrease in cGFR of >20 per cent from the baseline cGFR), while 151 did not (non-AKI group). Both groups had similar baseline cGFRs. The AKI group developed a lower cGFR nadir (45 ± 27 versus 79 ± 39 ml/min/1.73 m2 for the non-AKI group; P < 0.001); was older (56 ± 18 years versus 52 ± 19 years for the non-AKI group; P = 0.033); had a higher prevalence of diabetes (19.6 per cent versus 9.3 per cent for the non-AKI group; P = 0.007); was more frequently treated with other nephrotoxic drugs (51 per cent versus 38 per cent for the non-AKI group; P = 0.024); used iodinated contrast more frequently (18 per cent versus 8 per cent for the non-AKI group; P = 0.0054); and showed a higher prevalence of hypotension (63 per cent versus 44 per cent for the non-AKI group; P = 0.0003), shock (56 per cent versus 31 per cent for the non-AKI group; P < 0.0001), and jaundice (19 per cent versus 8 per cent for the non-AKI group; P = 0.0036). The mortality rate was 44.5 per cent for the AKI group and 29.1 per cent for the non-AKI group (P = 0.0031). A logistic regression model identified as significant (P < 0.05) the following independent factors that affected aminoglycoside-associated nephrotoxicity: a baseline cGFR of <60 ml/min/1.73 m2 (odds ratio [OR], 0.42), diabetes (OR, 2.13), treatment with other nephrotoxins (OR, 1.61) or iodinated contrast (OR, 2.13), and hypotension (OR, 1.83). (To continue) In conclusion, AKI was frequent among ICU patients receiving an aminoglycoside, and it was associated with a high rate of mortality. The presence of diabetes or hypotension and the use of other nephrotoxic drugs and iodinated contrast were independent risk factors for the development of aminoglycoside-associated nephrotoxicity

CNPq

Identificador

Antimicrobial Agents and Chemotherapy, Washington, v. 53, n. 7, p. 2887-2891, Jul. 2009

0066-4804

http://producao.usp.br/handle/BDPI/13379

10.1128/AAC.01430-08

http://aac.asm.org/content/53/7/2887.full.pdf+html

Idioma(s)

eng

Publicador

Washington

Relação

Antimicrobial Agents and Chemotherapy

Direitos

restrictedAccess

Copyright by the American Society for Microbiology

Palavras-Chave #TOXINAS (PREVALÊNCIA) #AMINOGLICOSÍDEOS (PREVALÊNCIA;TOXICIDADE;ASSOCIAÇÃO;TERAPIA) #FATORES DE RISCO #UNIDADES DE TERAPIA INTENSIVA
Tipo

article

original article

publishedVersion